Literature DB >> 16517708

Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

Andrés López-Albaitero1, Jayakar V Nayak, Takeshi Ogino, Avinash Machandia, William Gooding, Albert B DeLeo, Soldano Ferrone, Robert L Ferris.   

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) cells are poorly recognized in vitro by CTL despite expressing the restricting HLA class I allele and the targeted tumor Ag (TA). Several lines of evidence indicate that the lack of SCCHN cell recognition by CTL reflects defects in targeted TA peptide presentation by HLA class I Ag to CTL because of Ag-processing machinery (APM) dysfunction. First, lack of recognition of SCCHN cells by CTL is associated with marked down-regulation of the IFN-gamma-inducible APM components low-m.w. protein 2, TAP1, TAP2, and tapasin. Second, SCCHN cell recognition by CTL is restored by pulsing cells with exogenous targeted TA peptide. Third, the restoration of CTL recognition following incubation of SCCHN cells with IFN-gamma is associated with a significant (p = 0.001) up-regulation of the APM components TAP1, TAP2, and tapasin. Lastly, and most conclusively, SCCHN cell recognition by CTL is restored by transfection with wild-type TAP1 cDNA. Our findings may explain the association between APM component down-regulation and poor clinical course of the disease in SCCHN. Furthermore, the regulatory nature of the APM defects in SCCHN cells suggests that intralesional administration of IFN-gamma may have a beneficial effect on the clinical course of the disease and on T cell-based immunotherapy of SCCHN by restoring SCCHN cell recognition by CTL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517708     DOI: 10.4049/jimmunol.176.6.3402

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

Review 2.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

3.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

4.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

Review 5.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

6.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Authors:  Hyun-Bae Jie; Yu Lei; Jing Li; Neil Gildener-Leapman; Sumita Trivedi; Tony Green; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

Review 8.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

9.  Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; William Gooding; Robert L Ferris
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

10.  Amyloid precursor-like protein 2 association with HLA class I molecules.

Authors:  Amit Tuli; Mahak Sharma; Xiaojian Wang; Laura C Simone; Haley L Capek; Steven Cate; William H Hildebrand; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2009-01-31       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.